CXCL10 and ovarian carcinoma: In contrast, high CXCL9, CXCL10, and CXCL11 expression in the TME of patients with colorectal, oesophageal, non-small cell lung (NSCL) and ovarian cancer is an indicator of improved overall survival (27, 49–51), while it is a poor prognostic marker in patients with localized clear-cell RCC (52).